当前位置:循环首页>正文

[IHF2010]经导管主动脉瓣置入术——G.P.Ussia教授专访

作者:  G.P.Ussia教授   日期:2010/8/29 14:39:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

<International Circulation>: Improvements in heathcare actually leads to the increase in the incidence of some conditions, such as aortic valve calcification. Aortic valve calcification in elderly patients can cause aortic stenosis and because age has increased risk for all kinds of complications and multiple organ dysfunctions, the risk of surgery is very high. Recently, percutaneous aortic valve implantation has presented itself as an appropriate therapy for these special patients. Can you outline the indications and contraindications for the procedure?

    <International Circulation>: Improvements in heathcare actually leads to the increase in the incidence of some conditions, such as aortic valve calcification. Aortic valve calcification in elderly patients can cause aortic stenosis and because age has increased risk for all kinds of complications and multiple organ dysfunctions, the risk of surgery is very high. Recently, percutaneous aortic valve implantation has presented itself as an appropriate therapy for these special patients. Can you outline the indications and contraindications for the procedure?

    Dr Ussia: Aortic stenosis is the most frequent valvulopathy in the elderly population in Western countries. So there is a large need to be able to treat these patients with less risk. Most of the elderly patients have higher cardiac surgery risk for several reasons due specifically to age: frailty and because very often they have co-morbidities. Additionally very often they are anxious and afraid of the prospect of surgery.
    This new device, the transcatheter aortic valve prosthesis, is a biological valve, and in Europe is available for clinical use as two types.  The technology is  young having appeared on the market only three years ago and for this reason at the moment the indication for its use is in patients judged at high risk for surgical aortic valve replacement.
So the indications would be patients around 75 years of age with a EuroSCORE more than 20% or an STS-PROM score more than 10% or patients with porcelain aorta,  liver cirrhosis, hostile thorax, with previous coronary artery bypass operation, or those that are very frail assessed by the frailty index score.
    There is also indication for patients who have already had an aortic valve replacement with a biological prosthesis which is dysfunctional. We have seen with both types of valves that are available – the self-expanding and the balloon expandable – we can treat with very good results, previous surgical aortic biological valve malfunction due to restenosis or regurgitation.
    There are few contraindications to this procedure mainly for unfavorable anatomy assessed during the screening phase with echocardiography, angiography, and angio CT scan.   

[1]  [2]  [3]  下一页

版面编辑:沈会会  责任编辑:张衡



G.P.Ussia教授 冠心病 经导管主动脉瓣置入术

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530